Since a lack of evidence has been found on the role of TRAF3IP2 in cancer, we first determined its clinical implication by comparing the expression of TRAF3IP2 in both NONO-TFE3 tRCC and clear cell renal cell carcinoma (ccRCC). Here, TRAF3IP2 is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.